In vitro modulation of MMP-2 and MMP-9 in pediatric human sarcoma cell lines by cytokines, inducers and inhibitors

International Journal of Oncology

Volumn 44, Issue 1, 2014, Pages 27-34

  Roomi, M W ^a   Kalinovsky, T ^a   Rath, M ^a   Niedzwiecki, Aleksandra ^a  

^a Dr Rath Research Institute   (United States)

Author keywords

Cytokines; Inducers; Inhibitors; Matrix metalloproteinases; Osteosarcoma; Rhabdomyosarcoma

Indexed keywords

CYTOKINE; DACTINOMYCIN; DEXAMETHASONE; DOXYCYCLINE; EPIGALLOCATECHIN GALLATE; GELATINASE A; GELATINASE B; INTERLEUKIN 1BETA; LIPOPOLYSACCHARIDE; MITOGENIC AGENT; PHORBOL 13 ACETATE 12 MYRISTATE; RETINOIC ACID; TUMOR NECROSIS FACTOR ALPHA;

ARTICLE; CANCER CELL CULTURE; CELL METABOLISM; CONTROLLED STUDY; DOSE RESPONSE; DOWN REGULATION; ENZYME ACTIVITY; HUMAN; HUMAN CELL; IN VITRO STUDY; OSTEOSARCOMA; PRIORITY JOURNAL; PROTEIN SECRETION; RHABDOMYOSARCOMA; ZYMOGRAPHY;

CATECHIN; CELL LINE, TUMOR; CHILD; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MATRIX METALLOPROTEINASE 2; MATRIX METALLOPROTEINASE 9; MATRIX METALLOPROTEINASE INHIBITORS; OSTEOSARCOMA; PEDIATRICS; RHABDOMYOSARCOMA; SARCOMA; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84891906945     PISSN: 10196439     EISSN: 17912423     Source Type: Journal    
DOI: 10.3892/ijo.2013.2159     Document Type: Article

References (49)

1. National Institute of Health: PubMed Health: Osteosarcoma. http://www.ncbi.nlm.nih.gov/pubmedhealth/PMH0002616/. Accessed March 18, 2013. Last revised 10/2012.
2. Kaste SC, Pratt CB, Cain AM, Jones-Wallace DJ and Rao BN: Metastases detected at the time of diagnosis of primary pediatric extremity osteosarcoma at diagnosis: imaging features. Cancer 86: 1602-1608, 1999.
3. American Cancer Society: Osteosarcoma: What are the survival rates for osteosarcoma? http://www.cancer.org/cancer/osteosarcoma/detailedguide/ osteosarcoma-survival-rates. Accessed March 18, 2013. Last revised 01/17/2013.
4. National Cancer Institute: Childhood Soft Tissue Sarcoma Treatment (PDQ®) http://www.cancer.gov/cancertopics/pdq/treatment/child-soft-tissue- sarcoma/HealthProfessional/. Accessed March 18, 2013. Last updated 12/3/2012.
5. Patham DM: Pathologic classification of rhabdomyosarcoma and correlations with molecular studies. Med Pathol 14: 506-514, 2001.
6. Mandell L, Ghavinni F, LaQuaglia M and Exelby P: Prognostic significance of regional lymph node involvements in childhood extremity rhabdomyosarcoma. Med Pediatr Oncol 18: 466-471, 1990.
7. Koscielniak E, Rodary C, Flamant F, Carli M, Treuner J, Pinkerton CR and Grono P: Metastatic rhabdomyosarcoma and histologically similar tumors in childhood: a retrospective European multi-center analysis, Med Pediatr Oncol 20: 209-214, 1992.
8. Benassi MS, Gamberi G, Magagnoli G, Molendini L, Ragazzini P, Merli M, Chiesa F, Balladelli A, Manfrini M, Bertoni F, Mercri M and Picci P: Metalloproteinase expression and prognosis in soft tissue sarcomas. Ann Oncol 12: 75-80, 2001.
9. Nelson AR, Fingleton B, Rothenberg ML and Matrisian LM: Matrix metalloproteinases: biologic activity and clinical implications. J Clin Oncol 18: 1135-1149, 2000.
10. Liotta LA, Tryggvason K, Garbisa A, Hart I, Foltz CM and Shafie S: Metastatic potential correlates with enzymatic degradation of basement membrane collagen. Nature 284: 67-68, 1980.
11. Stetler-Stevenson WG: The role of matrix metalloproteinases in tumor invasion, metastasis and angiogenesis. Surg Oncol Clin North Am 10: 383-392, 2001.
12. Stetler-Stevenson WG: Type IV collagenases in tumor invasion and metastasis. Cancer Metastasis Rev 9: 289-303, 1990.
13. Sato T, Sakai T, Noguchi Y, Takta M, Hirakawa S and Ito A: Tumor-stromal cell contact promotes invasion of human uterine cervical carcinoma cells by augmenting the expression and activation of stromal matrix metalloproteinases. Gynecol Oncol 92: 47-56, 2004.
14. Pyke C, Kristensen P, Ralfkiaer E, Gröndahl-Hansen J, Eriksen J, Blasi F and Danø K: Urokinase-type plasminogen activator is expressed in stromal cells and its receptor in cancer cells at invasive foci in human colon adenocarcinomas. Am J Pathol 138: 1059-1067, 1991.
15. Harvey P, Clark IM, Jourand MC, Warn RM and Edwards DR: Hepatocyte growth factor/scatter factor enhances the invasion of mesothelioma cell lines and the expression of matrix metalloproteinases. Br J Cancer 83: 1147-1153, 2000.
16. Liu Z, Ivanoff A and Klominek J: Expression and activity of matrix metalloproteases in human malignant mesothelioma cell lines. Int J Cancer 91: 638-643, 2001.
17. Vincent MP, White LA, Schroen DJ, Benbow U and Brinckerhoff CE: Regulating expression of the gene for matrix metalloproteinase-1 (collagenase): mechanisms that control enzyme activity, transcription and mRNA stability. Crit Rev Eukaryot Gene Expr 6: 391-411, 1996.
18. Rutkowski P, Kaminska J, Kowalska M, Ruka W and Steffen J: Cytokine and cytokine receptor serum levels in soft tissue sarcoma patients: correlations with clinico-pathological features and prognosis. Int J Cancer 100: 463-471, 2002.
19. Himelstein BP, Asada N, Carlton MR and Collins MH: Matrix metalloproteinase-9 (MMP-9) expression in childhood osseous osteosarcoma. Med Pediatr Oncol 31: 471-474, 1998.
20. Ferrari C, Benassi S, Ponticelli F, Gamberi G, Ragazzini P, Pazzaglia L, Balladelli A, Bertoni F and Picci P: Role of MMP-9 and its tissue inhibitor TIMP-1 in human osteosarcoma: findings in 42 patients followed for 1-16 years. Acta Orthop Scand 75: 487-491, 2004.
21. Bjornland K, Flatmark K, Pettersen S, Aaasen AO, Fodstad O and Maelandsmo GM: Matrix metalloproteinases participate in osteosarcoma invasion. J Surg Res 127: 151-156, 2005.
22. Roebuck MM, Helliwell TR, Chaudhry IH, Kalogrianitis S, Carter S, Kemp G, Ritchie DA, Jane MJ and Frostick SP: Matrix metalloproteinase expression is related to angiogenesis and histologic grade in spindle cell soft tissue neoplasms of the extremities. Am J Clin Pathol 123: 405-414, 2005.
23. Diomedi-Carnassei F, Boldrini R, Rava L, Donfrancesco A, Boglino C, Messina E, Dominici C and Callea F: Different patterns of matrix metalloproteinase expression in alveolar versus embryonal rhabdomyosarcoma. J Pediatr Surg 39: 1673-1679, 2004.
24. Ray JM and Stetler-Stevenson WG: The role of matrix metalloproteinase and their inhibitors in tumour invasion, metastasis and angiogenesis. Eur Respir J 7: 2062-2072, 1994.
25. Apodaca G, Rutka JT, Bouhana K, Berens ME, Giblin JR, Rosenblum ML, McKerrow JH and Banda MJ: Expression of metalloproteinases and metalloproteinase inhibitors by fetal astrocytes and glioma cells. Cancer Res 50: 2322-2329, 1990.
26. Linder C, Linder S, Munck-Wickland E and Strander H: Independent expression of serum vascular endothelial growth factor (VEGF) and basic fibroblast growth factor (bFGF) in patients with carcinoma and sarcoma. Anticancer Res 18(3B): 2063-2068, 1998.
27. Graeven U, Andre N, Achilles E, Zornig C and Schmeigel W: Serum levels of vascular endothelial growth factor and basic fibroblast growth factor in patients with soft-tissue sarcoma. J Cancer Res Clin Oncol 125: 577-581, 1999.
28. Rutkowski P, Kaminska J, Kowalska M, Ruka W and Steffen J: Cytokine and cytokine receptor serum levels in adult bone sarcoma patients: correlations with local tumor extent and prognosis. J Surg Oncol 84: 151-159, 2003.
29. Niedzwiecki A, Roomi MW, Kalinovsky T and Rath M: Micronutrient synergy - a new tool in effective control of metastasis and other key mechanisms of cancer. Cancer Metastasis Rev 29: 529-543, 2010.
30. Roomi MW, Monterrey JC, Kalinovsky T, Niedzwiecki A and Rath M: Inhibition of invasion and MMPs by a nutrient mixture in human cancer cell lines: a correlation study. Exp Oncol 32: 243-248, 2010.
31. Roomi MW, Monterrey JC, Kalinovsky T, Rath M and Niedzwiecki A: Comparative effects of EGCG, green tea and a nutrient mixture on the patterns of MMP-2 and MMP-9 expression in cancer cell lines. Oncol Rep 24: 747-757, 2010.
32. Rath M and Pauling L: Plasmin-induced proteolysis and the role of apoprotein(a), lysine and synthetic analogs. Orthomolecular Med 7: 17-23, 1992.
33. Sun Z, Chen YH, Wang P, Zhang J, Gurewich V, Zhang P and Liu JN: The blockage of high-affinity lysine binding sites of plasminogen by EACA significantly inhibits prourokinase-induced plasminogen activation. Biochem Biophys Acta 1596: 182-192, 2002.
34. Valcic S, Timmermann BN, Alberts DS, Wachter GA, Krutzsch M, Wymer J and Guillen JM: Inhibitory effect of six green tea catechins and caffeine on the growth of four selected human tumor cell lines. Anticancer Drugs 7: 461-468, 1996.
35. Mukhtar H and Ahmed N: Tea polyphenols: prevention of cancer and optimizing health. Am J Clin Nutr 71: S1698-S1702, 2000.
36. Yang GY, Liao J, Kim K, Yurtow EJ and Yang CS: Inhibition of growth and induction of apoptosis in human cancer cell lines by tea polyphenols. Carcinogenesis 19: 611-616 1998.
37. Taniguchi S, Fujiki H, Kobayashi H, Go H, Miyado K, Sadano H and Shimikawa R: Effect of (-) epigallocatechin gallate, the main constituent of green tea, on lung metastasis with mouse B16 melanoma cell lines. Cancer Lett 65: 51-54, 1992.
38. Hara Y: Green Tea: Health Benefits and Applications. Marcel Dekker, New York, NY, 2001.
39. Kawakami S, Kageyama Y, Fujii Y, Kihara K and Oshima H: Inhibitory effects of N-acetyl cysteine on invasion and MMP 9 production of T24 human bladder cancer cells. Anticancer Res 21: 213-219, 2001.
40. Morini M, Cai T, Aluigi MG, Noonan DM, Masiello L, De Floro S, D'Agostinin F, Albini A and Fassima G: The role of the thiol N-acetyl cysteine in the prevention of tumor invasion and angiogenesis. Int J Biol Markers 14: 268-271, 1999.
41. Yoon SO, Kim MM and Chung AS: Inhibitory effects of selenite on invasion of HT 1080 tumor cells. J Biol Chem 276: 20085-20092, 2001.
42. Naidu KA, Karl RC and Coppola D: Antiproliferative and proapoptotic effect of ascorbyl stearate in human pancreatic cancer cells: association with decreased expression of insulin-like growth factor 1 receptor. Dig Dis Sci 48: 230-237, 2003.
43. Anthony HM and Schorah CJ: Severe hypovitaminosis C in lung-cancer patients: the utilization of vitamin C in surgical repair and lymphocyte-related host resistance. Br J Cancer 46: 354-367, 1982.
44. Maramag C, Menon M, Balaji KC, Reddy PG and Laxmanan S: Effect of vitamin C on prostate cancer cells in vitro: effect on cell number, viability and DNA synthesis. Prostate 32: 188-195, 1997.
45. Koh WS, Lee SJ, Lee H, Park C, Park MH, Kim WS, Yoon SS, Park K, Hong SI, Chung MH and Park CH: Differential effects and transport kinetics of ascorbate derivatives in leukemic cell lines. Anticancer Res 8: 2487-2493, 1998.
46. Chen Q, Espey MG, Krishna MC, Mitchell JB, Corpe CP, Buettner GR, Shacter E and Levine M: Pharmacologic ascorbic acid concentrations selectively kill cancer cells: action as a pro-drug to deliver hydrogen peroxide to tissues. Proc Natl Acad Sci USA 102: 13604-13609, 2005.
47. Nunez C, Ortiz de Apodaca Y and Ruiz A: Ascorbic acid in the plasma and blood cells of women with breast cancer. The effect of consumption of food with an elevated content of this vitamin. Nutr Hosp 10: 368-372, 1995.
48. Kurbacher CM, Wagner U, Kolster B, Andreotti PE, Krebs D and Bruckner HW: Ascorbic acid (vitamin C) improves the antineoplastic activity of doxorubicin, cisplatin and paclitaxel in human breast carcinoma cells in vitro. Cancer Lett 103: 183-189, 1996.
49. Cooke JP and Dzau VJ: Nitric oxide synthase: Role in the genesis of vascular disease. Annu Rev Med 48: 489-509, 1997.